Shire’s $30bn move on Baxalta

Pharma giant Shire has made an unsolicited $30bn all-share offer for America’s Baxalta.

15-8-6-Shire-634
Shire is testing investors' tolerance

Pharmaceuticals giant Shire, Dublin-based and UK-listed, has made an unsolicited $30bn all-share offer for America's Baxalta. Shire said a tie-up with Baxalta would produce a group with $20bn in sales by 2020. Shire's shares fell on the news. The pharma mergers and acquisitions boom shows no sign of cooling: $400bn of transactions have been announced since January, 80% up from the same period in 2014.

What the commentators said

But there's also "a fair slug of industrial logic", said Neil Unmack on breakingviews.com. Putting the two groups together should produce a strong presence in haemophilia, and as it grows its global presence, it will gain the scale to invest in new drugs, boost prices and beef up marketing, with a view to becoming a leader in rare disease drugs. Yet Shire shareholders seem unconvinced, said Helen Thomas in The Wall Street Journal.

One worry is that Baxalta's haemophilia drugs, which account for half of sales, are about to face competition. What's more, the price is worth a hefty 16 times operating earnings, and is only likely to go higher as negotiations get underway. Shire's recent appetite for "ever bigger, more risky dealmaking is testing investors' tolerance".

Recommended

The race for a coronavirus vaccine heats up
Biotech stocks

The race for a coronavirus vaccine heats up

Biotech shares, led by AstraZeneca, are lifted in the race to come up with a coronavirus vaccine.
28 Aug 2020
Profit from the fast growth of the haircare industry
Share tips

Profit from the fast growth of the haircare industry

Our society has become much more image-conscious, while new consumers worldwide want to look good too. From shampoos to new potential cures for baldne…
6 Aug 2020
Which Covid-19 vaccines look likely to be the best bets?
Biotech stocks

Which Covid-19 vaccines look likely to be the best bets?

The race to produce a treatment to prevent Covid-19 has hundreds of entrants. How should investors approach it? Matthew Partridge reports.
24 Jul 2020
Syncona: a biotech trust that's going for a song
Investment trusts

Syncona: a biotech trust that's going for a song

Syncona is an investment trust that invests in promising, privately-held biotechnology companies. It looks too cheap.
15 Jun 2020

Most Popular

Here’s why you really should own at least some bitcoin
Bitcoin

Here’s why you really should own at least some bitcoin

While bitcoin is having a quiet year – at least in relative terms – its potential to become the default cash system for the internet is undiminished, …
16 Sep 2020
Will a second wave of Covid lead to another stockmarket crash?
Stockmarkets

Will a second wave of Covid lead to another stockmarket crash?

Can we expect to see another lockdown like in March, and what will that mean for your money? John Stepek explains.
18 Sep 2020
Central banks want politicians to take charge – but what will they do?
US Economy

Central banks want politicians to take charge – but what will they do?

The US Federal Reserve has come to the end of the road in terms of what it can do to accelerate any recovery, says John Stepek. It's over to the polit…
17 Sep 2020